Pfizer, Inc. (NYSE:PFE) EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pfizer, Inc. (NYSE:PFE) opened at $35.55 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.34 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $211.70 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 2.45 and a beta of 1.01. Pfizer, Inc. has a fifty-two week low of $29.90 and a fifty-two week high of $36.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 EPS. equities research analysts forecast that Pfizer, Inc. will post 2.59 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. Pfizer’s payout ratio is currently 78.53%.

TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/alexander-r-mackenzie-sells-7350-shares-of-pfizer-inc-pfe-stock/1677632.html.

A number of research firms have recently commented on PFE. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday. Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday. UBS Group AG (USA) set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday. Finally, Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.35.

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer during the 2nd quarter worth $103,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the period. Herndon Capital Management LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer during the 1st quarter worth $121,000. Institutional investors and hedge funds own 69.01% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.